I
Inoveon
Medical services company that delivers solutions to detect, and stage and monitor diseases affecting the eye,
About Inoveon
Inoveon operates in the healthcare sector, specializing in diabetic eye care. The company provides a comprehensive system for the detection, staging, monitoring, and treatment of diabetic retinopathy and macular edema. This system is designed to target patients for early intervention, thereby preventing blindness in the adult working-aged population. Inoveon collaborates with board-certified retinal specialists to offer a range of sight-preserving treatments. The company serves a diverse clientele including primary care settings, corporate self-insured entities, eye clinics, ophthalmologists, endocrinology practices, government agencies, VA, Indian Health Services, and correctional facilities.
Inoveon's business model is centered around a turn-key solution that integrates detection, monitoring, and therapy into one service. This model allows clients to manage their budgets effectively and cap costs. Revenue is generated through service contracts with healthcare providers and institutions that require specialized diabetic eye care solutions.
Source: Dealroom company dataAt a glance
- Founded
- 1999
- Headquarters
- Oklahoma City, United States
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
CenterPoint Venture Partners
Chrysalis Ventures
Prolog Ventures- MCMassey Burch Capital Corporation
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Inoveon on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Inoveon on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.